Pregabalin controlled substance
Pro Research Analysisby 
Searched over 200M research papers
Pregabalin as a Controlled Substance: An Overview
Reclassification of Pregabalin and Gabapentin
UK Government's Decision to Reclassify
The UK government has decided to reclassify pregabalin and gabapentin as class C controlled substances starting from April next year. This decision aims to address the increasing number of deaths associated with the misuse of these drugs 12. The reclassification follows expert advice and a Home Office consultation, which highlighted the need to tackle the misuse and addiction linked to these medications .
BMA's Advocacy for Reclassification
The British Medical Association (BMA) has also advocated for the reclassification of pregabalin as a controlled drug. During their annual representative meeting, delegates voted in favor of lobbying the appropriate authorities to make this change. The BMA's stance underscores the widespread issues of misuse and addiction associated with pregabalin .
Abuse Potential and Clinical Concerns
Abuse Potential of Pregabalin
Several studies and case reports have raised concerns about the abuse potential of pregabalin. It has been noted that pregabalin can cause euphoric and dissociative effects, especially when taken in doses exceeding the normal therapeutic range or through alternative routes of administration such as nasal insufflation or venous injection . Clinical studies have reported euphoria as a frequent side effect, particularly among patients with a history of substance abuse .
Effects in Combination with Opioids
Research has also explored the effects of pregabalin when used in combination with opioids like oxycodone. While pregabalin alone did not significantly increase abuse-related subjective effects, its combination with oxycodone altered some subjective effects, although it did not increase the liking of oxycodone . This suggests a complex interaction that warrants further investigation to fully understand the abuse liability of pregabalin.
Clinical Use and Efficacy
Approved Uses and Efficacy
Pregabalin is approved for the treatment of neuropathic pain, fibromyalgia, and as an adjunctive therapy for partial-onset seizures. It has demonstrated efficacy in managing conditions such as painful diabetic neuropathy and postherpetic neuralgia . Despite its therapeutic benefits, the potential for abuse and dependence has led to its designation as a Schedule V controlled substance in the United States .
Safety and Adverse Effects
Clinical trials have shown that pregabalin is effective and rapidly acting in treating generalized anxiety disorder, with a favorable safety profile. Common adverse effects include somnolence and dizziness, but no serious adverse events or withdrawal syndromes have been reported . However, the potential for misuse and the associated risks necessitate careful monitoring by prescribers, especially in patients with a history of substance abuse .
Conclusion
The reclassification of pregabalin as a controlled substance reflects growing concerns about its misuse and the associated health risks. While pregabalin remains an effective treatment for various neuropathic and anxiety disorders, its potential for abuse and dependence underscores the need for vigilant prescribing practices and further research into its psychopharmacological effects.
Sources and full results
Most relevant research papers on this topic
Subjective, Psychomotor, and Physiological Effects of Pregabalin Alone and in Combination With Oxycodone in Healthy Volunteers
Pregabalin may increase subjective effects and decrease respiration rate when combined with oxycodone, but does not increase drug liking or desire to take the drug again.
Pregabalin: an antiepileptic agent useful for neuropathic pain.
Pregabalin may be beneficial for treating neuropathic pain or partial-onset seizures in patients who do not respond to conventional treatments or cannot tolerate their adverse effects.
DOI